Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical
technology business, today announces the publication of a
randomised controlled trial (RCT) demonstrating that the addition
of ALLEVYN LIFE, Smith & Nephew’s leading multi-layer silicone
adhesive foam dressing, to a standard care protocol significantly
reduces the onset of pressure ulcers by 71% in elderly patients
admitted to hospital for hip fracture1.
Published in the International Wound Journal, the RCT charts the
experience of 359 fragile hip fracture patients aged 65 or over.
These patients were randomly divided into two groups, with some
receiving standard care and others receiving standard care with the
addition of an ALLEVYN LIFE dressing applied to the sacrum.
15.4% of patients receiving standard care developed a pressure
ulcer as opposed to only 4.5% of the group who received the same
care with the addition of ALLEVYN LIFE resulting in a 71% reduction
in pressure ulcer incidence.
“Hip fractures in the elderly are a serious problem due to the
high rate of mortality and complications such as pressure ulcers,
which occur mainly in the sacral area,” said Professor Cristiana
Forni, Head of a research nursing centre, Rizzoli Orthopaedic
Institute, Bologna, Italy “Preventive measures play an important
role in increasing quality of care, reducing health costs and
improving the patient’s quality of life. Our research shows that
ALLEVYN LIFE is effective at reducing the rate of pressure ulcers
in the sacrum in elderly patients with hip fracture. The excellent
adhesiveness of this device also enables costs to be kept
down.”
This new study adds to the growing body of evidence
demonstrating the effectiveness of ALLEVYN LIFE in multi-component
pressure ulcer prevention programmes1-5. Prophylactic dressings do
not negate the need for thorough and regular skin assessment and
should be used as part of a comprehensive pressure ulcer prevention
protocol.
“Many global experts and professional bodies8 state polyurethane
foam dressings should be considered for use prophylactically on
bony prominences in anatomical areas subject to friction and shear”
said Dr Andy Weymann, Chief Medical Officer, Smith & Nephew.
“This new research further demonstrates that ALLEVYN LIFE is a safe
and effective preventative measure suited to be at the heart of a
pressure ulcer prevention strategy.”
ALLEVYN LIFE has been designed following observational
ethnographic research with patients and clinicians to address unmet
needs in wound management. The dressing has a five layer design
incorporating a breathable top layer, hydrocellular foam,
hyper-absorbent lock away core, masking layer, silicone gel
adhesive layer and wide border. ALLEVYN LIFE Sacrum has a unique
tail designed specifically for wounds in the sacral area and fits
around the cleft, to help overcome common problems such as the
dressing tenting.
To learn how we can help you get CLOSER TO ZERO™ pressure ulcer
incidence, please visit www.smith-nephew.com/forni
References
1. Forni C, D’Alessandro F, Gallerani P, et
al. Effectiveness of using a new poly-urethane foam multi-layer
dressing in the sacral area to prevent the onset of pressure ulcer
in the elderly with hip fractures: A pragmatic randomised
con-trolled trial. Int Wound J. 2018;1–8.
2. Clarke, B: Positive patient outcomes: The
use of a new silicone adhesive hydrocellular foam dressing for
pressure ulcer prevention and treatment
3. Lisco, C: Evaluation of a new silicone
gel-adhesive hydrocellular foam dressing as part of a pressure
ulcer prevention plan for ICU patients
4. Brindle, T: Preventing sacral pressure
ulcer development in the surgical patient population
5. Sammon, M: Reducing Hospital-acquired
pressure injuries and the cost of prevention in the OR and ICU
setting
6. Data on File report DS/15/217/R Oct 2015,
L. Daubney. Pressure transmission testing
7. Data on File report GMCA-DOF/08-April
2016, A. Rossington. Product performance of the next generation
ALLEVYN LIFE
8. National Pressure Ulcer Advisory Panel,
European Pressure Ulcer Advisory Panel and Pan Pacifi c Pressure
Injury Alliance. Prevention and Treatment of Pressure Ulcers:
Clinical Practice Guideline. Emily Haesler (Ed.) Cambridge Media:
Osborne Park, Western Australia; 2014.
About Smith & Nephew Smith & Nephew is a global
medical technology business dedicated to helping healthcare
professionals improve people's lives. With leadership positions in
Orthopaedic Reconstruction, Advanced Wound Management, Sports
Medicine and Trauma & Extremities, Smith & Nephew has
around 15,000 employees and a presence in more than 100 countries.
Annual sales in 2017 were almost $4.8 billion. Smith & Nephew
is a member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com.
To learn more about what we do to help reduce pressure ulcer
incidence, please visit www.closertozero.com
Forward-looking Statements This document may contain
forward-looking statements that may or may not prove accurate. For
example, statements regarding expected revenue growth and trading
margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target",
"consider" and similar expressions are generally intended to
identify forward-looking statements. Forward-looking statements
involve known and unknown risks, uncertainties and other important
factors that could cause actual results to differ materially from
what is expressed or implied by the statements. For Smith &
Nephew, these factors include: economic and financial conditions in
the markets we serve, especially those affecting health care
providers, payers and customers; price levels for established and
innovative medical devices; developments in medical technology;
regulatory approvals, reimbursement decisions or other government
actions; product defects or recalls or other problems with quality
management systems or failure to comply with related regulations;
litigation relating to patent or other claims; legal compliance
risks and related investigative, remedial or enforcement actions;
disruption to our supply chain or operations or those of our
suppliers; competition for qualified personnel; strategic actions,
including acquisitions and dispositions, our success in performing
due diligence, valuing and integrating acquired businesses;
disruption that may result from transactions or other changes we
make in our business plans or organisation to adapt to market
developments; and numerous other matters that affect us or our
markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents
that Smith & Nephew has filed with the U.S. Securities and
Exchange Commission under the U.S. Securities Exchange Act of 1934,
as amended, including Smith & Nephew's most recent annual
report on Form 20-F, for a discussion of certain of these factors.
Any forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
◊ Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180215005456/en/
MediaRoad CommunicationsBeth Lowes+44 (0) 208 995
5832beth@roadcommunications.co.ukorSmith & NephewDave Snyder+1
(978) 749-1440
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Apr 2023 to Apr 2024